Looking Ahead at the Neurology Clinical Trial Space in the Post-COVID-19 Landscape

For pharmaceutical and medical device companies, navigating the neurology clinical trial space in the wake of COVID-19 requires balancing between critical study milestones and patient safety. With the post-pandemic landscape becoming the new clinical trial status quo, neurology research must now execute the best strategies available to adapt and pivot quickly across all central nervous system (CNS) studies. Today’s neurological studies now need to take into account the patient burden, clinical site safety, and even pre-existing neurological conditions caused by the COVID-19 infection to reach successful trial completion.

Register for this webinar to hear experts from Biorasi take a deep dive into what neurological clinical trials will look like beyond COVID-19 protocols.

  Sign up today at